Efficient intracellular delivery of proteins is needed to fully realize the potential of protein therapeutics. Current methods of protein delivery commonly suffer from low tolerance for serum, poor endosomal escape and limited in vivo efficacy. Here we report that common cationic lipid nucleic acid transfection reagents can potently deliver proteins that are fused to negatively supercharged proteins, that contain natural anionic domains or that natively bind to anionic nucleic acids. This approach mediates the potent delivery of nM concentrations of Cre recombinase, TALE-and Cas9-based transcription activators, and Cas9:sgRNA nuclease complexes into cultured human cells in media containing 10% serum. Delivery of unmodified Cas9:sgRNA complexes resulted in up to 80% genome modification with substantially higher specificity compared to DNA transfection. This approach also mediated efficient delivery of Cre recombinase and Cas9:sgRNA complexes into the mouse inner ear in vivo, achieving 90% Cre-mediated recombination and 20% Cas9-mediated genome modification in hair cells.
Therapeutic proteins including peptide hormones 1 , cytokines 2 and monoclonal antibodies 3 have achieved widespread success as research tools and are among the fastest growing classes of drugs 4 . Many powerful and potentially therapeutic proteins have been discovered or engineered over the past two decades, including enzymes capable of metabolic complementation 5 , neutralizing antibodies against intracellular targets 6 , engineered transcription factors 7 and programmable genome-editing enzymes 8 . Although protein biologics have proven effective for extracellular targets, their use to address intracellular targets is comparatively undeveloped because most proteins are unable to spontaneously enter mammalian cells. Enabling exogenous proteins to access intracellular targets is most commonly achieved by delivery of their encoding DNA sequences through chemical transfection 9 , electroporation 10 or viral delivery 11 . The introduction of exogenous DNA into cells, however, raises the possibility of permanent recombination into the genome, potential disruption of endogenous genes and long-term exposure to the encoded agent. The recent development of methods to deliver in vitro-transcribed mRNAs or mRNA analogs has offered an alternative to DNA delivery without requiring nuclear transport of an encoding gene, and with greatly reduced potential for genomic insertion of the foreign nucleic acid. Although promising, mRNA delivery continues to face challenges including immunogenicity and RNA stability 12 . For genome editing applications that seek to effect a one-time, permanent modification of genomic DNA, the functional delivery of nonreplicable protein agents may offer improved specificity, increased safety and broader applicability.
We and others have previously developed protein delivery technologies based on fusion or conjugation to cationic molecules that facilitate endocytosis, such as unstructured peptides 13, 14 or engineered, superpositively charged proteins [15] [16] [17] . Although such methods can be effective in cell culture 15, 17 and have even shown some success in vivo, they have not been widely adopted. Unprotected proteins can be rapidly degraded by extracellular and endosomal proteases, or neutralized by binding to serum proteins, blood cells and the extracellular matrix 18 . In addition, the low efficiency of endosomal escape and avoidance of lysosomal degradation are major challenges to all endocytic protein delivery strategies, as evidenced by ongoing interest in endosome altering 17 and destabilizing strategies 19 . These challenges have proven especially difficult in vivo 20 .
Nucleic acid delivery has benefited greatly from the development of liposomal reagents over the past two decades. Cationic lipid formulations have enabled DNA and RNA transfection to become a routine technique in basic research and have even been used in clinical trials 21 . The lipid bilayer of the vehicle protects complexed nucleic acids from degradation and can prevent neutralization by antibodies 22 . Notably, fusion of liposomes with the endosomal membrane during endosome maturation can enable the efficient endosomal escape of cationic, lipiddelivered cargo 23 .
Because proteins, in contrast to nucleic acids, are chemically diverse with no dominant electrostatic property, no lipid formulation is likely to drive the efficient delivery of all proteins into mammalian cells. Whereas proteins can be complexed nonspecifically and delivered by rehydrated lipids in vitro 18 , protein complexation is dependent on high protein concentrations, is generally inefficient 24 and has not been widely adopted. Specialty commercial reagents developed for protein delivery 25, 26 have shown modest and variable efficiency with different protein cargoes 27 .
We hypothesized that proteins that are highly anionic could be delivered by the same electrostatics-driven complexation used by cationic liposomal reagents for nucleic acid delivery ( Fig. 1a) . Although few proteins natively possess the highly anionic character of nucleic acids, we speculated that translational fusion or noncovalent complexation with a polyanionic molecule may render the resulting protein or protein complex sufficiently anionic to be efficiently delivered by common cationic lipid reagents. We demonstrate that fusion of proteins with an engineered, supernegatively charged GFP 28 enables efficient complexation and delivery of proteins into cultured mammalian cells by cationic lipids. Our approach is effective even at low nanomolar protein concentrations and in the presence of serum, requiring 1,000-fold less protein to achieve similar functional protein delivery levels than methods that use fusion to cationic peptides or proteins 15 . We further show that Cas9 (clustered, regularly interspaced, short palindromic repeats (CRISPR)associated (Cas)) nuclease protein complexed with polyanionic single guide RNA (sgRNA) can be efficiently delivered in functional form into mammalian cells using cationic lipid formulations. Delivery of Cas9:sgRNA complexes is highly efficient (up to 80% modification of cultured human cells from a single treatment) and also induces higher genome modification specificity (typically about tenfold) compared with plasmid transfection. Finally, we demonstrate that this protein delivery approach can be effective in vivo by delivering functional Cre recombinase and functional Cas9:sgRNA complexes to hair cells in the inner ear of live mice. These findings suggest that the intracellular delivery of polyanionic proteins and protein:nucleic acid complexes by cationic lipids may greatly expand the scope of research and therapeutic applications of proteins.
RESULTS
Delivery of Cre recombinase fused to anionic proteins First, we tested whether the engineered, supernegatively charged GFP variant 28 , (-30)GFP, could mediate complexation and delivery of Figure 1 Strategy for delivering proteins into mammalian cells by fusion or noncovalent complexation with polyanionic macromolecules and complexation with cationic lipids. (a) Recombinases, TALE proteins and Cas9 endonucleases bind nucleic acids and are natively cationic (net theoretical charges are shown in black) and are not efficiently complexed with cationic lipids. These proteins can be rendered highly anionic, however, by fusion to either a supernegatively charged protein such as (-30)GFP, or by complexation with polyanionic nucleic acids. (b) We envisioned that cationic lipids commonly used to transfect DNA and RNA would complex with the resulting highly anionic proteins or protein:nucleic acid complexes, mediating their delivery into mammalian cells. A R T I C L E S npg of (-30)GFP-Cre protein was much less toxic than plasmid transfection ( Supplementary Fig. 1c,d ). In addition, flow cytometry revealed that the high potency of lipid-mediated delivery of (-30)GFP-Cre does not arise from unusually high protein uptake in each cell, but rather from postendocytosis processes, which likely include endosomal escape and/or the avoidance of lysosomal protein degradation ( Supplementary Fig. 2 and Supplementary Results). These observations collectively indicate that cationic lipids can mediate the potent delivery of polyanionic proteins into mammalian cells, even in the presence of serum, and with low toxicity.
To test whether the ability to deliver polyanionic proteins is dependent on proprietary components in RNAiMAX or whether other cationic lipids are capable of mediating similarly potent delivery, we tested several other transfection reagents designed to deliver nucleic acids. Several, but not all, cationic lipid formulations tested potently delivered negatively charged proteins into human cells ( Fig. 2e and Supplementary Results).
Several other polyanionic proteins, including the VP64 transcription activation domain (-22 net theoretical charge), (-20)GFP, (-7)GFP and the 3× FLAG epitope tag (-7 net theoretical charge), all enhanced cationic lipid-mediated delivery of Cre in a charge-dependent manner ( Fig. 2f and Supplementary Results). Collectively these results suggest that protein delivery efficacy by cationic lipids is predominantly a function of total negative charge and does not require a particular distribution of anionic residues.
Functional delivery of transcription activator-like effector (TALE) proteins
Next we tested lipid-mediated delivery of TALE-VP64 transcription activators into HEK293T cells. Although modestly effective cleavage of endogenous genes by delivered TALE nucleases (TALEN) has been demonstrated in mammalian cells in the absence of serum using cationic peptides 29 , the delivery of TALE-based transcription factor proteins has not yet been reported, and no effective delivery of TALE proteins in serum-containing media has been previously described to our knowledge. We targeted the gene for neurotrophin-3 (NTF3), a neural growth factor that when mutated has been associated with neurodegenerative diseases and hearing loss 30 . We fused a previously described NTF3-targeting fused protein cargo ( Fig. 1b) . We translationally fused (-30)GFP to Cre recombinase to generate (-30)GFP-Cre; note that (-30) refers to the net theoretical charge of the GFP moiety, not the net charge of the fusion. We assayed a variety of commercially available cationic lipids for their ability to functionally deliver (-30)GFP-Cre into HeLa cells that express DsRed only upon Cre-mediated recombination ( Fig. 2a) . Lipofectamine RNAiMAX, hereafter referred to as "RNAiMAX, " is a commercial reagent designed for delivery of short interfering RNAs (siRNAs). Delivery of 10 nM (-30)GFP-Cre complexed with 1.5 ml RNAiMAX in DMEM containing 10% fetal bovine serum (FBS) led to a strong DsRed fluorescence signal among treated cells. Flow cytometry revealed that 48 h after treatment, 52% of cells expressed DsRed, consistent with Cre recombination (Fig. 2b) .
Optimization resulted in recombination efficiencies of 65% using 25 nM (-30)GFP-Cre complexed with 1.5 ml RNAiMAX in 275 ml of DMEM containing 10% FBS (Fig. 2c) . The potency of lipid-mediated (-30)GFP-Cre delivery is remarkable when compared to that of cationic protein-mediated delivery. Only 1 nM (-30)GFP-Cre with cationic lipid was needed to yield 15-20% recombined cells, whereas 1 mM (+36)GFP-Cre was required to achieve this extent of recombination, corresponding to a 1,000-fold difference in the required protein dose (Fig. 2c ). Nearly identical results were observed in a second Cre reporter cell line (BSR TdTomato) ( Supplementary Fig.  1a ). Under the same conditions that deliver (-30)GFP-Cre most efficiently, cationic lipids did not increase the delivery potency of neutral or cationic Cre recombinase fusions ( Fig. 2c) , indicating that the highly negative charge of (-30)GFP-Cre is required to participate in cationic lipid-mediated protein delivery. We also observed that increasing the amount of cationic lipid increased the concentration of protein required for maximal recombination, consistent with a model in which deliverable proteins are complexed with specific stoichiometries of cationic lipids (Fig. 2d) .
To compare this method to standard plasmid DNA transfection, we optimized plasmid transfection on HeLa reporter cells. Optimized DNA transfection resulted in a maximum of 33% DsRed fluorescent cells ( Supplementary Fig. 1b) . We also observed that lipid-mediated delivery 
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A R T I C L E S npg tor activity following protein delivery peaks ~4 h post-treatment and falls over the next 44 h ( Fig. 3c) , whereas plasmid DNA transfection required ~24 h to show above-background levels of NTF3 activation, which plateaued at ~36-48 h (Fig. 3c) . These findings collectively demonstrate that TALE activator proteins can be delivered using cationic lipids to rapidly and transiently activate gene expression in human cells. This capability may prove especially valuable for proteins that induce a permanent change in cell state or cell fate when transiently expressed.
Functional delivery of Cas9:sgRNA protein:RNA complexes Given the potent lipid-mediated delivery of polyanionic Cre and TALE activator protein variants in full-serum media, we speculated that CRISPR-Cas9:sgRNA complexes, either as fusions with (-30)GFP or as native polyanionic Cas9:guide RNA complexes, might also be delivered into human cells using this approach. Using a well-established Cas9-induced gene disruption assay 32 , we targeted specific sites within a genomic EGFP reporter gene in human U2OS cells ( Supplementary  Fig. 4a ). On-target Cas9 cleavage induces nonhomologous end joining (NHEJ) in EGFP and the loss of cell fluorescence. To avoid interference from the fluorescence of (-30)GFP, we introduced a Y67S mutation into (-30)GFP to eliminate its fluorescence and designated TALE-VP64 (ref. 31 ) to (-30)GFP ( Fig. 3a) and treated HEK293T cells with 25 nM (-30)GFP-NTF3 TALE1-VP64 and 1.5 ml RNAiMAX under the conditions optimized for Cre delivery. Gene expression levels of NTF3 4 h after treatment were 3.5-fold higher in cells treated with 25 nM (-30) GFP-NTF3 TALE1-VP64 and RNAiMAX than in untreated cells, cells treated with RNAiMAX only, or cells treated with a VEGF-targeting TALE transcription activator (Fig. 3b) . Similar levels of NTF3 expression were observed 48 h after transfection of plasmids encoding the same NTF3targeting TALE-VP64 (Fig. 3b) .
As the synergistic expression of multiple TALE activators targeting different sites on the same gene has been shown to augment gene activation 31 , we simultaneously delivered five distinct NTF3-targeting TALE activators fused to (-30)GFP using RNAiMAX. Protein-lipid complexes were prepared as above by adding the five (-30)GFP-NTF3-TALE-VP64 proteins at 5 nM each, for a total of 25 nM protein. We observed an optimized sevenfold increase in NTF3 expression after a 4-h incubation ( Fig. 3b  and Supplementary Fig. 3a) , whereas plasmid co-transfection of all five NTF3 TALE activators, followed by a 48-h incubation, resulted in a similar tenfold increase in NTF3 expression levels (Fig. 3b) . To characterize TALE activity over time using these two methods, we measured NTF3 mRNA levels over a 48-h period following protein or DNA delivery. TALE activa- (Fig. 4a) . No significant EGFP disruption was observed upon transfection of plasmids encoding EGFP sgRNA alone, Cas9 alone, or cotransfection of plasmids encoding Cas9 and an sgRNA designed to target a VEGF locus ( Fig. 4a and Supplementary Fig. 4b) .
We confirmed that the robust disruption of EGFP was not a result of cellular toxicity (Supplementary Fig. 4c,d) . We also observed that treatment of cells with (+36)dGFP-NLS-Cas9 and sgRNA in the presence of 10% FBS did not lead to efficient gene disruption ( Fig. 4a) , suggesting that cationic-protein based methods of delivery for Cas9 and sgRNA may not be effective, perhaps due to interference of Cas9:sgRNA complex formation or nuclease function by cationic proteins 33 . This is consistent with a recent study describing the delivery of Cas9 protein with an oligoarginine peptide tag that achieved only moderate levels of gene disruption 34 . Optimization of plasmid transfection conditions did not yield higher than 40% EGFP disruption ( Fig. 4a and Supplementary Fig. 5a ), and the transfection conditions required to achieve this level of gene disruption resulted in high levels of cellular toxicity (Supplementary Fig. 5b ). Together, these results establish that cationic lipid-mediated delivery of (-30) dGFP-NLS-Cas9:sgRNA complexes can result in efficient, sgRNAdependent, target gene disruption in human cells with minimal toxicity, unlike cationic peptide-based protein delivery or plasmid DNA transfection methods.
Anionic sgRNA is necessary and sufficient for Cas9 delivery As the complex of native Cas9 protein (+22 net theoretical charge) and an sgRNA (~103 anionic phosphate groups) should be overall highly anionic, next we tested whether native Cas9:sgRNA complexes without fusion to polyanionic proteins can be delivered into human cells using cationic lipids. Treatment of U2OS EGFP reporter cells with 100 nM Cas9, 50 nM EGFP sgRNA and 0.8 ml RNAiMAX resulted in 65% disruption of the EGFP reporter gene (Fig. 4a) . These observations suggest that sgRNA alone, even in the absence of a supernegatively charged fusion protein, can provide the highly anionic character needed to mediate cationic lipid-based delivery of Cas9. We evaluated several different Cas9 constructs over a broad range of conditions ( Supplementary Fig. 6a-g and Supplementary Results) and lipid formulations ( Supplementary  Fig. 7a and Supplementary Results) for their effect on EGFP disruption and observed that up to 80% targeted gene disruption resulted from Cas9:sgRNA complexed with Lipofectamine 2000 (Fig. 4a) . Due to the modestly higher toxicity of Lipofectamine 2000 compared to RNAiMAX across a range of doses (Supplementary Fig. 7b-d and Supplementary  Results) , we continued using RNAiMAX for cell culture studies unless otherwise noted.
To verify that EGFP disruption arose from genome modification and not only from Cas9 binding 35 , we used the T7 endonuclease I (T7EI) assay 36 to detect and quantify the frequency of Cas9-mediated genomic insertion/deletion mutations (indels) at the target EGFP locus (Fig. 4b) .
The T7EI assay results showed that only those cells treated with both Cas9 and EGFP sgRNA plasmids, or Cas9 protein and purified EGFP sgRNA, contained indels at the target site 48 h after treatment. We also treated U2OS EGFP reporter cells with a single lipid-mediated delivery treatment of Cas9 complexed with a mixture of four sgRNAs targeting EGFP, CLTA, EMX and VEGF, resulting in cleavage efficiencies of 58%, 28%, 16% and 40%, respectively, as measured by T7EI cleavage assay (Fig. 4c) . These high gene-disruption efficiencies from a single delivery of 50 nM Cas9 and 12.5 nM of each sgRNA (50 nM total sgRNA) demonstrate that lipid-mediated Cas9:sgRNA delivery can support efficient multiplexed genome editing.
We also tested whether delivered Cas9 nuclease:sgRNA complexes are capable of effecting homology-directed repair (HDR) using an EGFPrepair reporter cell line 37 . We combined Cas9 and EGFP-targeting sgRNA, mixed the resulting protein:RNA complexes with varying concentrations of single-stranded DNA oligonucleotide (ssODN) donor template (Supplementary Notes) and delivered the Cas9:sgRNA + ssODN mixture using Lipofectamine 2000 (Supplementary Fig. 8a) . Cas9:sgRNA delivery achieved EGFP HDR frequencies of ~8-11%, similar to that of optimized plasmid transfection-based HDR (Supplementary Fig. 8b,c) , and consistent with previous reports using the same reporter cell line 37 , suggesting that cationic lipid-based delivery of Cas9:sgRNA is a viable approach to efficient HDR. Table 2 ). All protein:sgRNA deliveries and plasmid transfections were performed in 24-well format using 1.6 ml RNAiMAX in 550 ml DMEM-FBS without antibiotics. Error bars reflect s.d. from three biological replicates performed on different days.
A R T I C L E S npg ( Supplementary Fig. 13 and Supplementary Results) . We note that the majority of this protein likely exists within endosomes and may not be available to effect genome modification 17, 42 . Taken together, these results show that the delivery of Cas9:sgRNA complexes using cationic lipids can effect target gene modification at high efficiency and with substantially greater specificity than the delivery of DNA expressing Cas9 and sgRNA.
In vivo delivery of Cre recombinase and Cas9:sgRNA Efficient delivery of functional genome-editing proteins in vivo could enable a wide range of applications including nonviral therapeutic genome editing to correct genetic diseases. To evaluate this protein delivery method in a live animal, we chose delivery to the mouse inner ear due to its confined space, well-characterized inner ear cell types, and the existence of genetic deafness mouse models that may enable future hearing recovery studies. We attempted the in vivo delivery of two types of proteins into the mouse inner ear. First, we tested the delivery of (-30)GFP-Cre protein to assess the targeting of inner ear cell types and the efficiency of functional protein delivery. Second, we evaluated the delivery of Cas9:sgRNA complexes to the inner ear to determine whether cationic lipid-mediated protein:sgRNA complex delivery can support CRISPR-based gene editing in vivo.
We previously showed that (+36)GFP-Cre could be delivered to mouse retina 15 , although the protein resulted in only modest levels of recombinant conversion suggestive of inefficient in vivo delivery. For our initial inner ear delivery trials, we complexed (-30)GFP-Cre with RNAiMAX and injected the complex into the cochlea of postnatal day 1 (P1) reporter mice with a genomically integrated floxed-STOP tdTomato reporter. As with our in vitro Cre reporter cell line, functional delivery of Cre to the inner ear cells, followed by endosomal escape, nuclear localization and Cre-mediated recombination results in expression of tdTomato. After injection, the cochleas were harvested for immunolabeling with inner ear cell markers for co-localization with tdTomato. RNAiMAX injection alone was used as control. Five days following injection of (-30)GFP-Cre and RNAiMAX, cochlear outer hair cells, a type of auditory sensory cells that detects sound, showed strong tdTomato signal that co-localized with the hair cell marker myosin VIIa (Myo7a), demonstrating functional Cre delivery to hair cells (Fig. 6a,b) . No tdTomato expression was detected in control cochleas (Fig. 6a) . The tdTomato signal was concentrated in the region of the injection site at the basal turn of the cochlea. On average, 33 ± 3% of outer hair cells were tdTomato positive at the base of the cochlea (P < 0.001; mean ± s.e.m., n = 4), and intact sterocilia, indicative of healthy hair cells, were observed (Fig. 6b) . We also tested delivery using Lipofectamine 2000 due to its higher potency in vitro (Supplementary Fig. 7a ) and observed dramatically higher recombination efficiency: 91 ± 5% outer hair cells in cochleas treated with (-30)GFP-Cre + Lipofectamine 2000 were tdTomato positive (Fig.  6c) . In comparison to control samples, some outer hair cell loss was observed (Fig. 6c) , consistent with our previous observation of higher cell toxicity of Lipofectamine 2000, although overall cochlear architecture was preserved.
After validating Cas9:sgRNA delivery in reporter cells ( Fig. 4a-e) , and in neuron-derived mouse embryonic stem cells ( Supplementary  Fig. 14 and Supplementary Results) , we tested Cas9:sgRNA delivery in vivo. Cas9 and sgRNA targeting EGFP were combined with RNAiMAX, and the resulting complexes were injected into postnatal day 2 (P2) transgenic Atoh1-GFP mouse cochlea in which all hair cells express GFP under the control of a hair cell-specific enhancer for transcription factor Atoh1 (ref. 43 ). With this model, Cas9:sgRNA-mediated disruption of Atoh1-GFP resulted in loss of Next we determined whether cationic lipid-based protein delivery could be applied to deliver other Cas9-derived genome engineering tools such as Cas9 nickases 38 and Cas9-based transcription activators 39 . We measured gene disruption efficiency in U2OS EGFP reporter cells resulting from delivery of Cas9 D10A nickase ( Fig. 4d and Supplementary Results) and achieved results similar to previous reports using plasmid transfection 40 . Delivery of dCas9-VP64 activators either by plasmid transfection or RNAiMAX-mediated protein delivery resulted in strong (higher than about tenfold) activation of NTF3 transcription ( Fig. 4e and Supplementary Fig. 9a ). As observed above with TALE activators (Fig. 3c) , dCas9-VP64 protein delivery resulted in fast-acting and transient transcription activation compared to DNA delivery ( Supplementary Fig. 9b and Supplementary Results) . These results collectively indicate that both Cas9 nickases and Cas9 transcription activators can also be delivered effectively by cationic lipid-mediated protein:sgRNA complex delivery.
Cas9:sgRNA delivery improves genome modification specificity Transient delivery of functional Cas9:sgRNA protein:RNA complexes circumvents risks associated with viral or other gene delivery methods and has the potential to improve the specificity of genome editing by minimizing the opportunity of agents to modify off-target substrates after the target locus is modified, or to reverse on-target modification. To test whether our approach can disrupt endogenous genes in human cells, we targeted genomic loci in the EMX1, CLTA2 and VEGF genes owing to their potential biomedical relevance and their use in previous studies 32, 40, 41 of Cas9 off-target cleavage activity. Cationic lipid-mediated delivery of Cas9:sgRNA complexes into HEK293T cells resulted in robust cleavage of all three human genes with efficiencies similar to or greater than those of plasmid transfection methods as revealed by the T7EI assay ( Fig. 5a) .
To compare the endogenous gene modification specificity of plasmid versus protein:RNA delivery methods for Cas9, we amplified the ontarget locus as well as several known off-target sites ( Supplementary  Table 1 ) from genomic DNA isolated from HEK293T cells treated either by transfection of Cas9 and sgRNA expression plasmids, or by RNAiMAX-mediated Cas9:sgRNA complex delivery under conditions that resulted in similar on-target modification efficiencies. The indel frequencies at the 3 on-target and 11 off-target sites were assayed by high-throughput DNA sequencing (Supplementary Table 2 ). For all three target genes, the frequency of on-target DNA modification resulting from either plasmid or protein:sgRNA delivery was 10 ± 2% ( Supplementary Fig. 10) , enabling the comparison of off-target modification under conditions that result in very similar on-target modification efficiencies. Importantly, the frequency of off-target genome modification for all 11 off-target sites was lower from protein:sgRNA delivery compared with plasmid delivery (Supplementary Fig. 10a-c) , and as a result, the ratio of on-target to off-target modification ratio for all sites tested was up to 19-fold higher for protein:sgRNA delivery than for plasmid delivery (Fig. 5b-d) .
We also observed that the increase in specificity for Cas9 protein delivery relative to DNA transfection persists across a wide range of ontarget cleavage efficiencies (~1%, ~10% and ~40%) ( Supplementary  Fig. 11 and Supplementary Results) . This increase in specificity using protein delivery is consistent with the transient nature of the delivered protein:sgRNA complexes compared to plasmid transfection ( Supplementary Fig. 12 and Supplementary Results) . We also measured the amount of protein internalized by cells using our cationic lipid-based protein delivery approach and determined that ~4% of the total protein used in the treatment was internalized by cells A R T I C L E S npg lines, stem cell colonies and therapeutically relevant in vivo sites within the mouse inner ear. Our approach is highly efficient, producing modification rates similar to or exceeding those of established nucleic acid transfection methods in cell culture, and enabling Cre recombinase-and Cas9-mediated genome modification rates of up to 90% and 20%, respectively, within the inner ear hair cell population of live mice (Fig. 6c,d) . For Cas9 nuclease delivery, this approach also typically results in over tenfold more specific genome modification than traditional plasmid transfection ( Fig. 5b-d) , likely due to the transient window of Cas9 activity to which each genome is exposed (Supplementary Fig. 12 ) compared to DNA delivery methods, consistent with previous reports 44 .
Others groups have reported the in vivo delivery of Cas9 expression constructs in DNA or mRNA form 45, 46 . This study establishes that protein delivery is a viable approach to in vivo genome editing. Because the commercial lipid reagents used in the current study were optimized for the delivery of DNA and RNA, it is likely that future development of specific components of the liposomal formulation GFP fluorescence in outer hair cells. Ten days after injection of Cas9:sgRNA with cationic lipid, we observed the absence of GFP in 13% of outer hair cells near the injection site. In contrast, control cochlea injected with Cas9 protein and RNAiMAX without any sgRNA showed no loss of EGFP signal (Fig. 6d) . The outer hair cells of cochlea injected with Cas9:sgRNA RNAiMAX complexes appeared to be otherwise unaffected, with stereotypical expression of Myo7a and healthy nuclei, consistent with minimal hair cell toxicity (Fig.  6d) . High-throughput DNA sequencing of genomic DNA isolated from cochlea tissue samples revealed indels consistent with GFP target gene disruption in the treated samples, but not in the control samples that lacked sgRNA (Supplementary Fig. 15a) . In addition, we repeated inner ear in vivo delivery of Cas9:sgRNA using an sgRNA that targets the EMX gene, and we similarly observed indels in the EMX gene in treated animals, but not control animals (Supplementary Fig. 15b) .
As (-30)GFP-Cre complexed with Lipofectamine 2000 resulted in more efficient modification of the target hair cell population than (-30)GFP-Cre complexed with RNAiMAX (Fig. 6a,c) , we tested its use on Cas9:sgRNA delivery to Atoh1-GFP cochlea as above. We observed loss of GFP expression in 20 ± 3% of outer hair cells near the injection site after 10 d, whereas all outer hair cells maintained strong GFP expression in control cochlea injected with Cas9 and Lipofectamine 2000 but no sgRNA (Fig. 6d) . In contrast to modest hair cell loss observed following Lipofectamine 2000 delivery of (-30)GFP-Cre (Fig. 6c) , outer hair cells targeted by Cas9:sgRNA exhibited no obvious toxicity or structural alteration (Fig. 6d) .
As with (-30)GFP-Cre, virus-free, cationic lipid-mediated delivery of Cas9:sgRNA into the mouse inner ear successfully modified a specific genomic locus in the outer hair cell population, leading to loss of target gene expression. As nearly half of all types of genetic deafness arises from hair cell loss or dysfunction (http://hereditaryhearingloss.org/), our results suggest a potential strategy based on the delivery of Cas9:sgRNA complexes to genetically modify these cells to effect hearing recovery. Taken together, these findings suggest that cationic lipid-mediated delivery of genomeediting proteins can serve as a powerful tool and a potential in vivo strategy for the treatment of genetic disease.
DISCUSSION
Efficient intracellular protein delivery in vitro and especially in vivo has been a persistent challenge in biomedical research and protein therapeutics. Here we report a general strategy for protein delivery that makes use of anionic protein complexation with cationic liposomes. We used this method to deliver diverse protein classes, including the Cre tyrosine recombinase, TALE transcription activators, and Cas9 nucleases, nickases and transcription activators (Fig. 1a) 
